BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 23347213)

  • 1. Epstein-Barr virus infection and posttransplant lymphoproliferative disorder.
    Green M; Michaels MG
    Am J Transplant; 2013 Feb; 13 Suppl 3():41-54; quiz 54. PubMed ID: 23347213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.
    Allen UD; Preiksaitis JK;
    Clin Transplant; 2019 Sep; 33(9):e13652. PubMed ID: 31230381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roles of Epstein-Barr virus viral load monitoring in the prediction of posttransplant lymphoproliferative disorder in pediatric liver transplantation.
    Chen HS; Ho MC; Hu RH; Wu JF; Chen HL; Ni YH; Hsu HY; Jeng YM; Chang MH
    J Formos Med Assoc; 2019 Sep; 118(9):1362-1368. PubMed ID: 30612881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Changing Epidemiology of Posttransplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Recipients Over 30 Years: A Single-center Experience.
    Peters AC; Akinwumi MS; Cervera C; Mabilangan C; Ghosh S; Lai R; Iafolla M; Doucette K; Preiksaitis JK
    Transplantation; 2018 Sep; 102(9):1553-1562. PubMed ID: 29485513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients.
    Lee TC; Savoldo B; Rooney CM; Heslop HE; Gee AP; Caldwell Y; Barshes NR; Scott JD; Bristow LJ; O'Mahony CA; Goss JA
    Am J Transplant; 2005 Sep; 5(9):2222-8. PubMed ID: 16095501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr virus load for early detection of lymphoproliferative disorder in pediatric renal transplant recipients.
    Ishihara M; Tanaka E; Sato T; Chikamoto H; Hisano M; Akioka Y; Dohno S; Maeda A; Hattori M; Wakiguchi H; Fujieda M
    Clin Nephrol; 2011 Jul; 76(1):40-8. PubMed ID: 21722604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epstein-Barr virus-associated risk factors for post-transplant lymphoproliferative disease in pediatric liver transplant recipients.
    Quintero Bernabeu J; Juamperez J; Mercadal-Hally M; Larrarte King M; Gallego Melcon S; Gros Subias L; Sábado Álvarez C; Soler-Palacin P; Melendo Pérez S; Esperalba J; Navarro Jiménez A; Garrido Pontnou M; Camacho Soriano J; Hidalgo Llompart E; Bilbao Aguirre I; Charco Torra R
    Pediatr Transplant; 2022 Sep; 26(6):e14292. PubMed ID: 35466492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Epstein Barr viral load monitoring in mononuclear lymphocytes and serum of renal transplant recipients using a quantitative PCR protocol].
    Merlino C; Giacchino F; Bergallo M; Bonello F; Bollero C; Segoloni GP; Cavallo R
    G Ital Nefrol; 2003; 20(2):170-5. PubMed ID: 12746803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The IPTA Nashville Consensus Conference on Post-Transplant lymphoproliferative disorders after solid organ transplantation in children: III - Consensus guidelines for Epstein-Barr virus load and other biomarker monitoring.
    Preiksaitis J; Allen U; Bollard CM; Dharnidharka VR; Dulek DE; Green M; Martinez OM; Metes DM; Michaels MG; Smets F; Chinnock RE; Comoli P; Danziger-Isakov L; Dipchand AI; Esquivel CO; Ferry JA; Gross TG; Hayashi RJ; Höcker B; L'Huillier AG; Marks SD; Mazariegos GV; Squires J; Swerdlow SH; Trappe RU; Visner G; Webber SA; Wilkinson JD; Maecker-Kolhoff B
    Pediatr Transplant; 2024 Feb; 28(1):e14471. PubMed ID: 37294621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients.
    San-Juan R; Comoli P; Caillard S; Moulin B; Hirsch HH; Meylan P;
    Clin Microbiol Infect; 2014 Sep; 20 Suppl 7():109-18. PubMed ID: 24475976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case Report: Non-negligible Epstein-Barr virus-associated posttransplant lymphoproliferative disorders in a lung transplant recipient.
    Hu J; Yu YW; Han DS; Li XJ; Zhang YQ; Cai HL; Xiao YH; Zheng X
    Front Immunol; 2023; 14():1244534. PubMed ID: 37781359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of quantitative Epstein-Barr virus polymerase chain reaction and preemptive immunosuppression reduction in pediatric liver transplantation: a preliminary experience.
    Kogan-Liberman D; Burroughs M; Emre S; Moscona A; Shneider BL
    J Pediatr Gastroenterol Nutr; 2001 Oct; 33(4):445-9. PubMed ID: 11698761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation.
    Blaes AH; Cao Q; Wagner JE; Young JA; Weisdorf DJ; Brunstein CG
    Biol Blood Marrow Transplant; 2010 Feb; 16(2):287-91. PubMed ID: 19835968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease.
    Smets F; Latinne D; Bazin H; Reding R; Otte JB; Buts JP; Sokal EM
    Transplantation; 2002 May; 73(10):1603-10. PubMed ID: 12042647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
    Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
    Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adapted treatment of Epstein-Barr virus infection to prevent posttransplant lymphoproliferative disorder after heart transplantation.
    Choquet S; Varnous S; Deback C; Golmard JL; Leblond V
    Am J Transplant; 2014 Apr; 14(4):857-66. PubMed ID: 24666832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Posttransplant Lymphoproliferative Disorder Following Kidney Transplantation: A Review.
    Sprangers B; Riella LV; Dierickx D
    Am J Kidney Dis; 2021 Aug; 78(2):272-281. PubMed ID: 33774079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey.
    San-Juan R; Manuel O; Hirsch HH; Fernández-Ruiz M; López-Medrano F; Comoli P; Caillard S; Grossi P; Aguado JM; ;
    Clin Microbiol Infect; 2015 Jun; 21(6):604.e1-9. PubMed ID: 25686696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of antiviral prophylaxis and rituximab use with posttransplant lymphoproliferative disorders (PTLDs): A nationwide cohort study.
    Walti LN; Mugglin C; Sidler D; Mombelli M; Manuel O; Hirsch HH; Khanna N; Mueller N; Berger C; Boggian K; Garzoni C; Neofytos D; van Delden C; Hirzel C;
    Am J Transplant; 2021 Jul; 21(7):2532-2542. PubMed ID: 33289340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-infection of Cytomegalovirus and Epstein-Barr Virus Diminishes the Frequency of CD56
    Lam JKP; Azzi T; Hui KF; Wong AMG; McHugh D; Caduff N; Chan KH; Münz C; Chiang AKS
    Front Immunol; 2020; 11():1231. PubMed ID: 32625211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.